In the News.
In the News
- Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)
SITC Late-breaking Abstract Oral Presentation - November 2022 - TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma
SITC - November 2022 - Feasibility of eftilagimod alpha (soluble LAG-3 protein) combined with standard-of-care therapy in advanced non-small-cell lung cancer (NSCLC) adenocarcinomas - Initial results from INSIGHT 003
SITC - November 2022 - Results from a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma (NSCLC) patients
IASLC World Conference on Lung Cancer - August 2022 - A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
ASCO Oral Abstract Session - June 2022 - TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
ASCO - June 2022 - Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) to placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast carcinoma.
ESMO - May 2022 - Results from a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma (NSCLC) patients
ELCC - March 2022 - Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)
SITC (click here for poster with comments) - November 2021 - Final results from AIPAC: A phase IIb trial comparing eftilagimod alpha (soluble LAG-3 protein) in combination with weekly paclitaxel in HR+ HER2- MBC
SITC - November 2021 - A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC)
SITC - November 2021 - Advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial evaluating feasibility and safety of eftilagimod alpha combined with avelumab in advanced solid tumors
ESMO - September 2021 - Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced stage solid tumors.
ASCO (click here for poster with comments) - June 2021 - Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.
ASCO (click here for poster with comments) - June 2021 - Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
ASCO (click here for poster with comments) - June 2021 - Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients
SABCS - December 2020 - Initial results from a Phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 1st line non-small cell lung carcinoma (NSCLC)
ESMO - September 2020 - Initial results from a Phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer (HNSCC) patients
ESMO - September 2020 - Safety data from stratum D of the phase I INSIGHT platform trial evaluating feasibility of IMP321 (LAG-3Ig protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities
ESMO - September 2020 - The phase I INSIGHT platform trial: Strata A and B evaluating feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumors
ESMO - September 2020 - Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (a soluble LAG-3 protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: results from stratum D of the INSIGHT platform trial
ASCO - May 2020 - Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab
ASCO - May 2020 - Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab
AACR (poster with comments) - April 2020 - AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo-controlled, multinational Phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor-positive metastatic breast cancer
SABCS - December 2019 - Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab
SITC - November 2019 - TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic NSCLC, or recurrent PD-X refractory NSCLC or with recurrent or metastatic HNSCC receiving the soluble LAG-3 fusion protein eftilagimod alpha in combination with pembrolizumab
ASCO - June 2019 - The "INSIGHT" Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities.
ASCO - June 2019 - Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
ASCO - June 2019 - Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
SITC Oral Presentation - November 2018 - Results from a Phase I dose escalation trial (TACTImel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
SITC - November 2018 - Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321) together with pembrolizumab in unresectable or metastatic melanoma
Society for Melanoma Research - October 2018 - Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.
ASCO - June 2018 - Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.
ASCO - June 2018